PreciseDx is being advised by world-renowned experts in oncology. This Scientific Advisory Board brings their expertise to guide the direction of PreciseBreast, our commercially available AI-powered test predicting breast cancer recurrence. https://lnkd.in/ee-FeAza
PreciseDx
医疗和诊断实验室
New York，NY 1,619 位关注者
Innovating oncology diagnostics through the power of AI
关于我们
PreciseDx? is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array? (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.
- 网站
-
https://precisedx.ai/
PreciseDx的外部链接
- 所属行业
- 医疗和诊断实验室
- 规模
- 11-50 人
- 总部
- New York，NY
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
获取路线
Mount Sinai; PreciseDX; 1 Gustave L Levy Place
US，NY，New York，10029
PreciseDx员工
动态
-
PreciseDx转发了
PreciseDx is being advised by world-renowned experts in oncology. This Scientific Advisory Board brings their expertise to guide the direction of PreciseBreast, our commercially available AI-powered test predicting breast cancer recurrence.
PreciseDx Announces Formation of Scientific Advisory Board
prnewswire.com
-
We are incredibly excited to announce the completion of our Series B funding, securing over $20M. For more details, be sure to read the full announcement on our website: https://lnkd.in/eJJh7cZF #TissueIsTheIssue #HealthcareInnovation #BreastCancer?
-
-
Clinical Lab Products recently featured an article on PreciseDx's study, published in the Taylor & Francis Group's Journal of Medical Economics. The study highlights how our AI-driven PreciseBreast? platform significantly reduces healthcare costs and enhances patient care. Learn how the power of our advanced AI in assessing the risk of breast cancer recurrence is transforming oncology diagnostics?and creating better outcomes for patients:?https://lnkd.in/eemKqiHa #BreastCancer #AI #HealthcareInnovation #OncologyDiagnostics #PatientCare #PreciseDx #TissueIsTheIssue
Breast Cancer: Study Analyzes Impact of Risk of Recurrence
https://clpmag.com
-
Exciting news! The economic impact study for our PreciseBreast? (PDxBr) risk assessment has been published in the July issue of the Journal of Medical Economics. This study assessed the cost impact of using PreciseBreast?, an AI-augmented histopathology platform that predicts the 6-year risk of recurrence in early-stage invasive breast cancer patients to aid in the treatment decision process. ?? The findings are compelling: In a hypothetical cohort of 1 million female members, using PreciseBreast? as part of a recurrence risk evaluation resulted in a remarkable cost saving of $4M in just the first year, compared to the current standard of care alone. Over 6-years, savings increased to $12.5M. Learn more and gain valuable insights into AI in medicine:?https://lnkd.in/eRD4UnVe #tissueistheissue #HealthcareInnovation #BreastCancer #AIinMedicine #MedicalEconomics #PreciseDx
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast?(PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
prnewswire.com
-
As artificial intelligence?is providing greater utility in healthcare, is it time?to align these causes rather than view them as opposing forces? Validated AI?may?significantly enhance healthcare by improving diagnostics, fostering widespread adoption of personalized medicine, as well as reshaping various other facets of patient care. ? The American Medical Association terms this technology 'augmented intelligence' rather than ‘artificial intelligence,’ emphasizing its role in supporting, instead of replacing, human decision-making.? ? At PreciseDx, we recognize the?vital role of AI-based tools in working alongside the cancer care team. Termed ‘Quantitative AI?’, we offer an assistive technology that informs care team decision-making. By harnessing this?validated and published AI platform, we aim to empower healthcare providers with advanced diagnostic capabilities and personalized treatment insights to improve patient outcomes and drive innovation in healthcare. ? A recent report by the AMA explores the transformative potential of augmented intelligence in healthcare and provides practical guidance for physicians using AI-based tools. Explore the full report here:?https://lnkd.in/dVewapnj? ? #AugmentedIntelligence #PersonalizedMedicine #HealthcareInnovation #TissueIsTheIssue
Future of Health: The Emerging Landscape of Augmented | AMA
ama-assn.org
-
HIT Consultant Media recently featured our collaboration with COTA and Baptist Health South Florida. They detail PreciseBreast?'s potential advantages: - Faster Results: PreciseDx delivers results in just 48 hours, accelerating the treatment planning process. - Reduced Cost: At a significantly lower price point (80% reduction), the test could increase access to this vital information. - Improved Accuracy: By leveraging AI, PreciseBreast? may offer more precise risk assessment compared to traditional methods. Check out the full article for more information: https://lnkd.in/e4EQndTN Thank you, Fred Pennic! #TissueIsTheIssue
New AI Test Aims to Improve Breast Cancer Recurrence Prediction
hitconsultant.net
-
Exciting update from #ASCO2024! This weekend, our Co-Founder and Chief Medical Officer, Dr. Michael J. Donovan PhD, MD, presented at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting. His poster session showcased the findings from our ongoing collaboration with the Laboratory for Pathology Dordrecht Albert Schweitzer Hospital in the Netherlands (NTH). Since its conception, this collaboration has made remarkable achievements in advancing invasive breast cancer diagnostic and treatment protocols. We are incredibly proud of Dr. Donovan and our team's dedication to pushing the boundaries of precision oncology diagnostics to ultimately improve patient outcomes globally. For an in-depth look at the poster and to explore the detailed findings of this ongoing study, visit our website: https://lnkd.in/eAisDbr2 #TissueIsTheIssue #HealthcareInnovation #PreciseDx?
-
-
We're excited to continue this important work together to improve accuracy and precision in diagnostic treatment decisions!
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast? NEW YORK--Today, COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast? (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence. “AI has the potential to augment human learning and improve the accuracy and precision of cancer diagnostics and treatments,” said C. K. Wang, M.D., chief medical officer, COTA. “It is critical that we evaluate these tools against the current standard of care to validate their efficacy and build trust in AI and new technologies.” As long-term collaborators, COTA and Baptist Health South Florida will analyze the performance of PreciseDx’s clinical risk tool using curated real-world data. They will compare the results of PreciseBreast? to traditional pathology reviews and to 21-gene assay results to validate its performance. If the validation study is successful, Baptist Health South Florida will offer this AI-enabled testing to patients with IBC with the goal of expanding access to innovations in cancer care. Additional benefits include access to results in 48 hours and an 80% reduction in cost. Current pathology practices are manual and often subjective. The PreciseBreast? test is designed to improve clinical decision-making with AI-derived insights that give physicians and patients a clear understanding of the risk of recurring IBC. “AI has allowed us to take a giant leap forward in the accuracy, affordability and accessibility of tools to better understand and treat breast cancer,” said Gerardo Fernandez, M.D., co-founder and chief scientific officer of PreciseDx. “Access to COTA’s best-in-class, real-world data that provides comprehensive insights into the cancer journeys of diverse patient populations will power more advanced and accurate AI learnings.” "This collaboration underscores our commitment to advancing cancer diagnostics with the latest AI-driven solutions,” said Manmeet Ahluwalia, MD, MBA, FASCO, deputy director, Fernandez Family Foundation Endowed Chair in Cancer Research, chief of medical oncology, and chief scientific officer of Miami Cancer Institute, part of Baptist Health South Florida. “By combining state-of-the-art technology with real-world evidence, we are working to not only enhance our diagnostic precision but also improve accessibility that may ultimately empower both patients and physicians with timely, actionable insights.” #realworlddata #rwd #oncologyresearch #breastcancer #healthcareai
-
-
One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. To that end, it's crucial that clinical care teams accurately assess the risk of breast cancer recurrence in an effort to characterize the diagnosis properly and streamline treatment decisions. Today, we are announcing a new collaboration with COTA and Baptist Health South Florida to assess and validate the performance of our PreciseBreast? test to combat this pressing issue. The test seeks to validate the efficacy of the AI-enabled test and its ability to predict the likelihood of invasive breast cancer (IBC) recurrence. Head to our website to learn more about the exciting new collaboration: https://lnkd.in/ehArUHsH #TissueIsTheIssue #OncologyDiagnostics #PrecisionMedicine #Collaboration #Innovation
PreciseDx Resources | Our Publications | PreciseDx
https://precisedx.ai